(Q36720955)

15 August 2017

1 reference

title

Antiangiogenesis to treat cancer and intraocular neovascular disorders (English)

1 reference

15 August 2017

2

Napoleone Ferrara

1 reference

15 August 2017

Farbod Shojaei

1

1 reference

PubMed ID

17259997

15 August 2017

language of work or name

1 reference

29 January 2007

1 reference

15 August 2017

Laboratory Investigation

1 reference

15 August 2017

87

1 reference

15 August 2017

3

1 reference

15 August 2017

227-230

1 reference

https://scigraph.springernature.com/pub.10.1038/labinvest.3700526

15 August 2017

0 references

cites work

Endothelial cells and VEGF in vascular development

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

The biology of VEGF and its receptors

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

Angiogenesis as a therapeutic target

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

Causes and prevalence of visual impairment among adults in the United States

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

Pegaptanib for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

Ranibizumab for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

Tumor-associated endothelial cells with cytogenetic abnormalities.

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

Antiangiogenic therapy: a universal chemosensitization strategy for cancer?

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.3700526

7 January 2021

10.1038/LABINVEST.3700526

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17259997